Penilaian Cyfra 21-1 dan Cd8 pada NSCLC: Implikasi untuk Kemoterapi dan Prognosis di Medan
DOI:
https://doi.org/10.55642/phasij.v5i01.987Keywords:
Adenokarsinoma, Biomarker, CD8, CYFRA 21-1, Kanker Paru Bukan Sel kecil (KPKBSK)Abstract
Kanker paru, khususnya Kanker Paru Non-Small Cell (NSCLC), merupakan penyebab utama kematian akibat kanker di seluruh dunia. NSCLC stadium lanjut sering kali diobati dengan kemoterapi, sehingga pemahaman tentang biomarker sangat penting untuk prognosis dan respons pengobatan. Biomarker seperti CYFRA 21-1 dan CD8 sangat penting dalam menilai karakteristik tumor, respons imun, dan prognosis secara keseluruhan pada pasien NSCLC. Penelitian ini mengevaluasi implikasi klinis CYFRA 21-1 dan CD8 pada pasien NSCLC yang menjalani kemoterapi di Medan, Indonesia. Penelitian deskriptif observasional dilakukan terhadap 20 pasien NSCLC dari RSUP H. Adam Malik, RSUP Prof. Chairuddin P. Lubis, dan RS St. Dengan menggunakan total sampling, kadar CYFRA 21-1 dan CD8 dinilai. Analisis data dilakukan dengan menggunakan SPSS versi 26. Hasil: Penelitian ini menemukan bahwa semua peserta adalah laki-laki, dengan 55% berusia di atas 60 tahun. Adenokarsinoma adalah subtipe yang paling umum (60%), dan 70% pasien didiagnosis pada stadium IV A. Kadar CD8 menunjukkan rentang yang luas, yang menunjukkan respons imun yang bervariasi. Sebaliknya, tingkat CYFRA 21-1 menyoroti potensinya dalam memprediksi perkembangan penyakit. Studi ini menggarisbawahi pentingnya CYFRA 21-1 dan CD8 dalam menilai tingkat keparahan penyakit dan memandu strategi terapeutik, yang berpotensi meningkatkan hasil klinis dalam pengobatan NSCLC.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Cline DJ, Khokhar S, Benina N, Thorne G. B-356 Siemens CYFRA 21-1: an assay for measurement of cytokeratin fragment 21-1. Clin Chem. 2024;70(Supplement_1):hvae106-713.
Cooper WA. Lessons and opportunities from improved understanding of global lung cancer histological subtypes. Lancet Oncol [Internet]. 2023 Nov 1;24(11):1159–61. Available from: https://doi.org/10.1016/S1470-2045(23)00475-8
Dhanurdhar Y, Jagaty SK, Subhankar S, Behera D. Diagnostic and Prognostic Significance of Serum Biomarkers – Serum Amyloid A and CYFRA 21-1 in Lung Cancer. Int J Appl Basic Med Res [Internet]. 2023;13(2). Available from: https://journals.lww.com/ijab/fulltext/2023/13020/diagnostic_and_prognostic_significance_of_serum.7.aspx
Esmear T, Lall N. Lung Matters: Review on Lung Cancer and Therapeutic Possibilities of Medicinal Plants. Med Plants Cosmet Heal Dis. 2022;215–28.
Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019 Dec;5(12):1749–68.
Goodgame B, Viswanathan A, Zoole J, Gao F, Miller CR, Subramanian J, et al. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol. 2009;4(11):1370–4.
Indonesia PDP, Indonesia P, Indonesia I, Fisik P, Indonesia R. Pedoman nasional pelayanan kedokteran: Kanker paru. Jakarta Kementeri Kesehat Republik Indones. 2016;1–3.
Kataoka N, Katayama Y, Yamada T, Morimoto K, Takeda T, Okada A, et al. CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study. Transl Lung Cancer Res Vol 13, No 8 (August 31, 2024) Transl Lung Cancer Res [Internet]. 2024; Available from: https://tlcr.amegroups.org/article/view/89597
Kazmi SMH, Masood A, Gulzar S, Shafi A. Emerging Trends in Lung Cancer Presentation at a Leading Tertiary Oncology Center and the Need for Lung Cancer Screening in Pakistan. Cureus. 2024;16(9):e70381.
Liu D. Tumors and Cancers: Head–Neck–Heart–Lung–Gut. CRC Press; 2017.
Miyadera K, Kakuto S, Sugai M, Tsugitomi R, Amino Y, Uchibori K, et al. Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2024;16(21):3712.
Roosta Y, Valizadeh MA, Abbasi MA. Determining the Prevalence of Primary Lung Malignancies by Histopathological Types and Gender: A Five-year Study. Hormozgan Medical Journal. 2023; 27 (4): 219-226. Vol. 15, Chest. 2018. p. 2–6.
Sang J, Liu P, Wang M, Xu F, Ma J, Wei Z, et al. Stem-like CD8 T cells in stage I lung adenocarcinoma as a prognostic biomarker: A preliminary study. J Cancer Res Ther. 2024;20(2):669–77.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.
Umar H, Wahab HA, Attiq A, Amjad MW, Bukhari SNA, Ahmad W. Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC). Mutat Res - Fundam Mol Mech Mutagen [Internet]. 2024;828:111856. Available from: https://www.sciencedirect.com/science/article/pii/S002751072400006X
Warner ET. Race, place, and socioeconomic status: A path toward lung cancer early detection. Cancer [Internet]. 2022 Aug 15;128(16):3016–8. Available from: https://doi.org/10.1002/cncr.34330
Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol [Internet]. 2023 Nov 1;24(11):1206–18. Available from: https://doi.org/10.1016/S1470-2045(23)00444-8
Ziora P, Kiczmer P, Zaboklicka N, Wypyszyńska J, Stachura M, Sito Z, et al. Ten-Year Observational Study of Patients with Lung Adenocarcinoma: Clinical Outcomes, Prognostic Factors, and Five-Year Survival Rates [Internet]. Preprints. Preprints; 2024. Available from: http://dx.doi.org/10.20944/preprints202409.1687.v1
